SNTI insider trading
HealthcareSenti Biosciences, Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.
About Senti Biosciences, Inc.
Senti Biosciences, Inc., a clinical stage biotechnology company, develops cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. Its lead product candidates utilize off-the-shelf healthy adult donor derived natural killer (NK) cells to create CAR-NK cells outfitted with gene circuit technologies in various oncology indications with unmet need. The company's product candidates also include SENTI-202, a logic gated off-the-shelf CAR-NK cell therapy for the treatment of blood cancers and relapsed/refractory hematological malignancies, including acute myeloid leukemia; and SENTI-301A, an off-the-shelf CAR-NK cell therapy for the treatment of solid tumors and hepatocellular carcinoma. In addition, it develops the tumor-associated antigen and protective antigen paired discovery platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells. Further, its pipeline includes preclinical programs, which comprise a solid tumor cell therapy program; and partnered programs related to gene therapies for tissue-directed targets, as well as partnered programs related to cell therapies for regenerative medicines. The company has a strategic collaboration with Celest Therapeutics (Shanghai) Co. Ltd for the clinical development of SENTI-301A to treat solid tumors. Senti Biosciences, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
Company website: www.sentibio.com
SNTI insider activity at a glance
FilingIQ has scored 24 insider transactions for SNTI since Jun 8, 2022. The most recent filing in our index is dated Mar 9, 2026.
Across the full history, 0 open-market purchases
and 4 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on SNTI insider trades is 60.8/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Other Healthcare tickers with recent insider activity
Frequently asked
- How many insider trades does FilingIQ track for SNTI?
- FilingIQ tracks 24 Form 4 insider transactions for SNTI (Senti Biosciences, Inc.), covering filings from Jun 8, 2022 onwards. 2 of those were filed in the last 90 days.
- Are SNTI insiders net buyers or net sellers?
- Across the full Form 4 history for SNTI, 0 transactions (0%) were open-market purchases and 4 (17%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does SNTI insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
- What sector is SNTI in?
- Senti Biosciences, Inc. (SNTI) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $22.87M.
Methodology & sources
Every SNTI insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.